Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

XAGE vs WELL vs VTR vs HIMS vs TDOC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
XAGE
Longevity Health Holdings Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-99.9%
WELL
Welltower Inc.

REIT - Healthcare Facilities

Real EstateNYSE • US
Market Cap$149.25B
5Y Perf.+158.5%
VTR
Ventas, Inc.

REIT - Healthcare Facilities

Real EstateNYSE • US
Market Cap$41.15B
5Y Perf.+56.7%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+240.4%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-94.5%

XAGE vs WELL vs VTR vs HIMS vs TDOC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
XAGE logoXAGE
WELL logoWELL
VTR logoVTR
HIMS logoHIMS
TDOC logoTDOC
IndustryBiotechnologyREIT - Healthcare FacilitiesREIT - Healthcare FacilitiesMedical - Equipment & ServicesMedical - Healthcare Information Services
Market Cap$7M$149.25B$41.15B$6.63B$1.26B
Revenue (TTM)$1M$11.63B$6.13B$2.35B$2.51B
Net Income (TTM)$-6M$1.43B$260M$128M$-171M
Gross Margin54.6%39.1%-4.3%69.7%65.6%
Operating Margin-401.0%4.4%13.4%4.6%-7.6%
Forward P/E78.4x118.0x51.5x
Total Debt$639K$21.38B$13.22B$1.12B$1.04B
Cash & Equiv.$157K$5.03B$741M$229M$781M

XAGE vs WELL vs VTR vs HIMS vs TDOCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

XAGE
WELL
VTR
HIMS
TDOC
StockSep 21May 26Return
Longevity Health Ho… (XAGE)1000.1-99.9%
Welltower Inc. (WELL)100258.5+158.5%
Ventas, Inc. (VTR)100156.7+56.7%
Hims & Hers Health,… (HIMS)100340.4+240.4%
Teladoc Health, Inc. (TDOC)1005.5-94.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: XAGE vs WELL vs VTR vs HIMS vs TDOC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: WELL leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. Hims & Hers Health, Inc. is the stronger pick specifically for valuation and capital efficiency and operational efficiency and capital deployment. XAGE and VTR also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
XAGE
Longevity Health Holdings Inc.
The Growth Leader

XAGE ranks third and is worth considering specifically for growth.

  • 139.4% revenue growth vs TDOC's -1.5%
Best for: growth
WELL
Welltower Inc.
The Real Estate Income Play

WELL carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 223.1% 10Y total return vs HIMS's 161.9%
  • Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
  • 12.3% margin vs XAGE's -393.6%
  • 1.3% yield, 2-year raise streak, vs VTR's 2.1%, (3 stocks pay no dividend)
Best for: long-term compounding and sleep-well-at-night
VTR
Ventas, Inc.
The Real Estate Income Play

VTR is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 1 yrs, beta 0.01, yield 2.1%
  • Beta 0.01, yield 2.1%, current ratio 0.96x
  • Beta 0.01 vs HIMS's 2.40, lower leverage
Best for: income & stability and defensive
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • Lower P/E (51.5x vs 118.0x)
  • 6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0%
Best for: growth exposure
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthXAGE logoXAGE139.4% revenue growth vs TDOC's -1.5%
ValueHIMS logoHIMSLower P/E (51.5x vs 118.0x)
Quality / MarginsWELL logoWELL12.3% margin vs XAGE's -393.6%
Stability / SafetyVTR logoVTRBeta 0.01 vs HIMS's 2.40, lower leverage
DividendsWELL logoWELL1.3% yield, 2-year raise streak, vs VTR's 2.1%, (3 stocks pay no dividend)
Momentum (1Y)WELL logoWELL+42.7% vs XAGE's -92.6%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0%

XAGE vs WELL vs VTR vs HIMS vs TDOC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

XAGELongevity Health Holdings Inc.

Segment breakdown not available.

WELLWelltower Inc.
FY 2025
Senior Housing - Operating
81.1%$8.5B
Triple Net
11.4%$1.2B
Outpatient Medical
7.5%$782M
VTRVentas, Inc.
FY 2025
Senior Living Operations
74.0%$4.3B
Outpatient Medical And Research Portfolio
15.5%$898M
Triple Net Leased Properties
10.4%$602M
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M

XAGE vs WELL vs VTR vs HIMS vs TDOC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLVTRLAGGINGXAGE

Income & Cash Flow (Last 12 Months)

VTR leads this category, winning 2 of 6 comparable metrics.

WELL is the larger business by revenue, generating $11.6B annually — 7980.8x XAGE's $1M. WELL is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to XAGE's -3.9%. On growth, XAGE holds the edge at +19.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
RevenueTrailing 12 months$1M$11.6B$6.1B$2.3B$2.5B
EBITDAEarnings before interest/tax-$6M$2.8B$2.3B$164M$42M
Net IncomeAfter-tax profit-$6M$1.4B$260M$128M-$171M
Free Cash FlowCash after capex-$4M$2.5B$1.4B$73M$251M
Gross MarginGross profit ÷ Revenue+54.6%+39.1%-4.3%+69.7%+65.6%
Operating MarginEBIT ÷ Revenue-4.0%+4.4%+13.4%+4.6%-7.6%
Net MarginNet income ÷ Revenue-3.9%+12.3%+4.2%+5.5%-6.8%
FCF MarginFCF ÷ Revenue-2.6%+21.9%+22.4%+3.1%+10.0%
Rev. Growth (YoY)Latest quarter vs prior year+19.8%+40.3%+22.0%+28.4%-2.5%
EPS Growth (YoY)Latest quarter vs prior year-4.9%+22.5%0.0%-27.3%+32.1%
VTR leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

TDOC leads this category, winning 5 of 6 comparable metrics.

At 50.3x trailing earnings, HIMS trades at a 69% valuation discount to VTR's 160.3x P/E. On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than WELL's 66.4x.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
Market CapShares × price$7M$149.2B$41.1B$6.6B$1.3B
Enterprise ValueMkt cap + debt − cash$7M$165.6B$53.6B$7.5B$1.5B
Trailing P/EPrice ÷ TTM EPS-0.64x153.25x160.26x50.32x-6.11x
Forward P/EPrice ÷ next-FY EPS est.78.42x118.01x51.51x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple66.40x24.31x42.68x15.13x
Price / SalesMarket cap ÷ Revenue133.03x13.99x7.05x2.82x0.50x
Price / BookPrice ÷ Book value/share3.35x3.18x12.25x0.89x
Price / FCFMarket cap ÷ FCF52.41x31.25x89.61x4.40x
TDOC leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-103 for XAGE. WELL carries lower financial leverage with a 0.49x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs HIMS's 4/9, reflecting strong financial health.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
ROE (TTM)Return on equity-103.5%+3.5%+2.1%+23.7%-12.4%
ROA (TTM)Return on assets-173.9%+2.3%+1.0%+6.0%-5.9%
ROICReturn on invested capital-38.0%+0.5%+2.5%+10.7%-11.5%
ROCEReturn on capital employed-47.5%+0.6%+3.2%+10.9%-10.0%
Piotroski ScoreFundamental quality 0–947646
Debt / EquityFinancial leverage0.49x1.05x2.07x0.75x
Net DebtTotal debt minus cash$481,854$16.3B$12.5B$892M$259M
Cash & Equiv.Liquid assets$157,139$5.0B$741M$229M$781M
Total DebtShort + long-term debt$638,993$21.4B$13.2B$1.1B$1.0B
Interest CoverageEBIT ÷ Interest expense-293.50x0.26x1.40x-8.76x
HIMS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

WELL leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in WELL five years ago would be worth $30,234 today (with dividends reinvested), compared to $11 for XAGE. Over the past 12 months, WELL leads with a +42.7% total return vs XAGE's -92.6%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.5% vs XAGE's -89.8% — a key indicator of consistent wealth creation.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
YTD ReturnYear-to-date+6.4%+14.3%+12.6%-23.2%-1.3%
1-Year ReturnPast 12 months-92.6%+42.7%+33.9%-51.0%+1.5%
3-Year ReturnCumulative with dividends-99.9%+189.5%+94.2%+116.6%-73.3%
5-Year ReturnCumulative with dividends-99.9%+202.3%+74.8%+137.6%-95.4%
10-Year ReturnCumulative with dividends-99.9%+223.1%+65.0%+161.9%-41.1%
CAGR (3Y)Annualised 3-year return-89.8%+42.5%+24.8%+29.4%-35.6%
WELL leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

VTR leads this category, winning 2 of 2 comparable metrics.

VTR is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTR currently trades 97.8% from its 52-week high vs XAGE's 3.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
Beta (5Y)Sensitivity to S&P 5001.86x0.13x0.01x2.40x1.91x
52-Week HighHighest price in past year$8.27$219.59$88.50$70.43$9.77
52-Week LowLowest price in past year$0.23$142.65$61.76$13.74$4.40
% of 52W HighCurrent price vs 52-week peak+3.9%+97.0%+97.8%+36.4%+71.2%
RSI (14)Momentum oscillator 0–10048.560.256.254.574.1
Avg Volume (50D)Average daily shares traded1K2.6M3.4M34.9M5.5M
VTR leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — WELL and VTR each lead in 1 of 2 comparable metrics.

Analyst consensus: WELL as "Buy", VTR as "Buy", HIMS as "Hold", TDOC as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 4.9% for VTR (target: $91). For income investors, VTR offers the higher dividend yield at 2.15% vs WELL's 1.30%.

MetricXAGE logoXAGELongevity Health …WELL logoWELLWelltower Inc.VTR logoVTRVentas, Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHold
Price TargetConsensus 12-month target$226.50$90.80$29.67$7.58
# AnalystsCovering analysts34321942
Dividend YieldAnnual dividend ÷ price+1.3%+2.1%
Dividend StreakConsecutive years of raises21
Dividend / ShareAnnual DPS$2.76$1.86
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+1.4%0.0%
Evenly matched — WELL and VTR each lead in 1 of 2 comparable metrics.
Key Takeaway

VTR leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). TDOC leads in 1 (Valuation Metrics). 1 tied.

Best OverallVentas, Inc. (VTR)Leads 2 of 6 categories
Loading custom metrics...

XAGE vs WELL vs VTR vs HIMS vs TDOC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is XAGE or WELL or VTR or HIMS or TDOC a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Welltower Inc. (WELL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — XAGE or WELL or VTR or HIMS or TDOC?

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus Ventas, Inc. at 160. 3x. On forward P/E, Hims & Hers Health, Inc. is actually cheaper at 51. 5x.

03

Which is the better long-term investment — XAGE or WELL or VTR or HIMS or TDOC?

Over the past 5 years, Welltower Inc.

(WELL) delivered a total return of +202. 3%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: WELL returned +223. 1% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — XAGE or WELL or VTR or HIMS or TDOC?

By beta (market sensitivity over 5 years), Ventas, Inc.

(VTR) is the lower-risk stock at 0. 01β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 25184% more volatile than VTR relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 49% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — XAGE or WELL or VTR or HIMS or TDOC?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -11. 5% for Welltower Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — XAGE or WELL or VTR or HIMS or TDOC?

Welltower Inc.

(WELL) is the more profitable company, earning 8. 8% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VTR leads at 14. 2% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is XAGE or WELL or VTR or HIMS or TDOC more undervalued right now?

On forward earnings alone, Hims & Hers Health, Inc.

(HIMS) trades at 51. 5x forward P/E versus 118. 0x for Ventas, Inc. — 66. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

08

Which pays a better dividend — XAGE or WELL or VTR or HIMS or TDOC?

In this comparison, VTR (2.

1% yield), WELL (1. 3% yield) pay a dividend. XAGE, HIMS, TDOC do not pay a meaningful dividend and should not be held primarily for income.

09

Is XAGE or WELL or VTR or HIMS or TDOC better for a retirement portfolio?

For long-horizon retirement investors, Ventas, Inc.

(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VTR: +65. 0%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between XAGE and WELL and VTR and HIMS and TDOC?

These companies operate in different sectors (XAGE (Healthcare) and WELL (Real Estate) and VTR (Real Estate) and HIMS (Healthcare) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XAGE is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock. WELL, VTR pay a dividend while XAGE, HIMS, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

XAGE

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 987%
  • Gross Margin > 32%
Run This Screen
Stocks Like

WELL

High-Growth Compounder

  • Sector: Real Estate
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Net Margin > 7%
Run This Screen
Stocks Like

VTR

High-Growth Disruptor

  • Sector: Real Estate
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Dividend Yield > 0.8%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform XAGE and WELL and VTR and HIMS and TDOC on the metrics below

Revenue Growth>
%
(XAGE: 1975.5% · WELL: 40.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.